Eric Deconinck
Overview
Explore the profile of Eric Deconinck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
217
Citations
2477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Marcelis Q, Gatzios A, Deconinck E, Rogiers V, Desmedt B, Vanhaecke T
Regul Toxicol Pharmacol
. 2022 Sep;
135:105260.
PMID: 36067853
Allergic contact dermatitis (ACD) often associated with the topical use of perfumed products, remains one of the most common chronic skin disorders in Western countries. Since labelling of scented menstrual...
32.
Clement M, Cervoni J, Renosi F, Thevenot T, Felix S, Doussot A, et al.
Clin Res Hepatol Gastroenterol
. 2022 Aug;
46(8):102004.
PMID: 35961592
No abstract available.
33.
Poussard M, Angelot-Delettre F, Deconinck E
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954431
No benchmark treatment exists for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since the malignancy is chemo-sensitive, chemotherapy followed by hematopoietic stem cell transplantation remains an effective treatment. However, relapses frequently...
34.
Duchateau C, De Leersnijder C, Barhdadi S, Canfyn M, De Braekeleer K, Deconinck E
Drug Test Anal
. 2022 Aug;
14(10):1732-1743.
PMID: 35945003
Herbal products for smoking containing cannabidiol (CBD) are available as "low-tetrahydrocannabinol cannabis products" in most EU countries. In Belgium, Δ9-tetrahydrocannabinol (THC) content of these products must be less than 0.2%...
35.
Poussard M, Philippe L, Fredon M, Bole-Richard E, Biichle S, Renosi F, et al.
EJHaem
. 2022 Jul;
2(1):125-130.
PMID: 35846081
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect....
36.
Trad R, Warda W, Alcazer V, Neto Da Rocha M, Berceanu A, Nicod C, et al.
J Immunother Cancer
. 2022 Jul;
10(7).
PMID: 35803613
Background: Acute myeloid leukemia (AML) remains a very difficult disease to cure due to the persistence of leukemic stem cells (LSCs), which are resistant to different lines of chemotherapy and...
37.
De Leersnijder C, Duchateau C, De Braekeleer K, Deconinck E
Anal Bioanal Chem
. 2022 Jul;
414(22):6507-6520.
PMID: 35788421
A classical quantitative analysis in liquid chromatography is performed using either a one-point calibration or a calibration line, prepared using a reference standard of the compound(s) of interest. However, in...
38.
Ruggeri A, de Wreede L, Muller C, Crivello P, Bonneville E, Petersdorf E, et al.
Haematologica
. 2022 May;
108(2):645-652.
PMID: 35546480
No abstract available.
39.
Rabadan Moraes G, Pasquier F, Marzac C, Deconinck E, Damanti C, Leroy G, et al.
Br J Haematol
. 2022 Mar;
198(1):131-136.
PMID: 35355248
Myeloproliferative neoplasms (MPN) are mainly sporadic but inherited variants have been associated with higher risk development. Here, we identified an EPOR variant (EPOR ) in a large family diagnosed with...
40.
Onida F, Sbianchi G, Radujkovic A, Sockel K, Kroger N, Sierra J, et al.
Bone Marrow Transplant
. 2022 Mar;
57(6):896-902.
PMID: 35352038
Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC ...